AUSTRALIAN PRODUCT INFORMATION – GLUCOSE 5% FREEFLEX, GLUCOSE 5% & 10% (GLUCOSE, GLUCOSE MONOHYDRATE) SOLUTION FOR INJECTION

1 NAME OF THE MEDICINE

Glucose

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Glucose 10% is a sterile hypertonic solution of glucose monohydrate 10% w/v in Water for Injections, containing no preservatives. pH 3.5 to 6.5.

Glucose 5% Freeflex is a sterile isotonic solution of glucose monohydrate 5% w/v in Water for Injections, containing no preservatives. pH 3.5 to 6.5.

For the full list of excipients, see Section 6.1 List of excipients.

3 PHARMACEUTICAL FORM

Solution for Injection

Clear colourless to slightly yellow solution

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

The solutions are indicated for intravenous fluid therapy designed to correct deficiencies in energy levels. Glucose 5% is also used to correct hydration levels. The solutions may also be used as solvents for intravenously administered drugs where compatibility has been established.

4.2 DOSE AND METHOD OF ADMINISTRATION

Glucose 5% Injection may be administered intravenously via a peripheral vein. The maximum rate at which glucose can be administered without producing glycosuria is 0.5 g/kg/h.

Glucose 10% Injection is hypertonic and should preferably be administered via an IV catheter in a large central vein. If a peripheral vein is used a large arm vein should be selected and the infusion site changed daily. The rate of infusion should not exceed 0.5 g/kg/h to avoid glycosuria.

The dose of glucose is dependent on the age, weight and fluid, electrolyte, glucose and acid-base balance of the patient.
Solutions containing glucose should not be administered through the same lines as those containing whole blood due to the risk of haemolysis and clumping. It does not contain antimicrobials. For use in one patient, on one occasion only. Residue should be discarded. Care should be taken with intravenous administration and injection technique to avoid injection site reactions and infections.

### 4.3 CONTRAINDICATIONS
Glucose is contraindicated in the following:

- diabetic coma where blood sugar levels are excessively high
- glucose-galactose malabsorption syndrome
- anuria
- intraspinal or intracranial haemorrhage
- in dehydrated delirium tremens patients
- known allergy to corn (maize) and corn products
- patients at risk for ischaemic stroke
- use after an ischaemic stroke episode

### 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Glucose solutions should be used with caution in patients with overt or known subclinical diabetes mellitus, or with carbohydrate intolerance.

Intravenous administration of glucose solutions, especially as infusions, may cause fluid overload and a resultant dilution of serum electrolytes and possible peripheral and pulmonary oedema. Prolonged therapy should be monitored for changes in fluid balance, electrolyte concentration and acid/base balance.

Hyperglycaemia and glucosuria may occur as a result of an over rapid rate of infusion or metabolic insufficiency. Blood and urine glucose should be monitored regularly.

Glucose solutions should not be infused concomitantly through the same intravenous set as blood as agglomeration or haemolysis may occur.

Prolonged parenteral administration of glucose may affect insulin production. To avoid this it may be necessary to add insulin to the infusion. A review of the patient’s oral hypoglycaemic agent or insulin requirements may be necessary.

Avoid use after an ischaemic stroke episode as under this condition the induced lactic acidosis aggravates the damage of brain tissues.

Thiamine diphosphate cocarboxylase is an essential coenzyme in carbohydrate metabolism, therefore patients having thiamine deficiency should be treated cautiously with glucose injection. This is particularly important in patients who chronically abuse alcohol as this may precipitate an overt deficiency syndrome, e.g. Wernicke’s encephalopathy.
Use in the elderly
No data available.

Paediatric use
Glucose solutions, particularly hypertonic ones, should be used with care and under expert supervision in paediatric patients. Dosage should be adjusted accordingly. Use with caution in infants of diabetic mothers.

Effects on laboratory tests
No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS
Parenteral fluids, especially those containing sodium ions, should be administered with caution to patients receiving corticosteroids or corticotrophin.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility
No data available.

Use in pregnancy

Pregnancy Category B3
Safety in pregnancy has not been established. Use only when clearly needed and potential benefits outweigh risk to the foetus.

Use in lactation.
No data available

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)
Glucose 5% Injection is iso-osmotic with blood and may be administered intravenously via a peripheral vein. Local reactions such as phlebitis or venous thrombosis and extravasation may occur. A fever response and infection at the site of injection may also occur due to contamination of the solution or poor techniques of administration.

Hyperglycaemia and glycosuria may occur if glucose is administered at a rate greater than 0.5 g/kg/h. Disruption of the fluid and acid-base balance and dilution of electrolyte concentrations may occur during prolonged usage, resulting in oedema, hypokalaemia, hypomagnesaemia and hypophosphataemia (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE).

Vitamin B complex deficiency may occur with glucose administration.
Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Hyperglycaemia and glycosuria, if undetected, can lead to mental confusion, dehydration, hyperosmolar coma and death.

Treatment

Appropriate treatment may include decreasing the infusion rate of glucose and administration of insulin.

Fluid overload and biochemical imbalance resulting from overdosage and glucose solution should be treated with appropriate corrective therapy.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia) or 0800 764 766 (New Zealand).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Mechanism of action

Glucose is a monosaccharide that provides the principal source of energy for the body. It is also involved in many additional areas of protein and fat metabolism.

Clinical trials

No data available.

5.2 Pharmacokinetic properties

Absorption

Glucose is stored in the body as fat and in the muscles and liver as glycogen. When a rapid rise in blood sugar is required, glycogen quickly liberates glucose. However, when this supply is insufficient the body mobilises its fat stores to release energy.

Distribution

Glucose also has a protein sparing function in the body. In the absence of glucose, energy can be produced from oxidation of deaminated amino acid fractions.
Metabolism

Glucose is the probable source of glucuronic acid, hyaluronates and chondroitin sulphates and can be converted to a pentose used for nucleic acid formation.

Glucose is metabolised to carbon dioxide and water thus providing water for body hydration as well as calories.

Excretion

No data available

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

No data available

Carcinogenicity

No data available.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Water for Injection.

6.2 INCOMPATIBILITIES

Additives may be incompatible with glucose. Do not administer such preparations unless the solution is clear. Do not store solutions containing additives unless compatibility has been proven. While some incompatibilities are readily observed, one must be aware that subtle physical, chemical and pharmacological incompatibilities can occur. The medical literature, the package insert and other available sources of information should be reviewed for a thorough understanding of possible incompatibility problems. In particular, the product information document of any added medication should be checked for any incompatibility with the glucose injection.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C

6.5 NATURE AND CONTENTS OF CONTAINER

Glucose 5% injection in polyolefin freeflex® bags:
50 mL AUST R 144669 - 40, 60, 65 and 70 bags/carton.

100 mL AUST R 144671-40, 50, 55 and 60 bags/carton

250 mL AUST R 144672-20, 30, 35 and 40 bags/carton

500 mL AUST R 29599-1 bag/carton.

1000 mL AUST R 47389-1 bag/carton.

Glucose 10 % injection in freeflex® bags:

500 mL AUST R 29790 - 1 bag/carton.

Not all pack sizes are available

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical properties

Chemical structure

Chemical name alpha-D-(+)-glucopyranose.

\( C_6H_{12}O_6 \)

CAS number

14431-43-7

7 MEDICINE SCHEDULE (POISONS STANDARD)

Australia: Unscheduled
New Zealand: General Sales Medicine

8 SPONSOR

Fresenius Kabi Australia Pty Limited
Level 2, 2 Woodland Way Mount Kuring-gai NSW 2080
Australia
Telephone: (02) 9391 5555

Fresenius Kabi New Zealand Limited
60 Pavilion Drive
Airport Oaks, Auckland 2022
New Zealand
Freecall: 0800 144 892
### 9 DATE OF FIRST APPROVAL

9 May 2006

### 10 DATE OF REVISION

1st August 2019

**Summary table of changes**

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>New format</td>
</tr>
<tr>
<td>4.9</td>
<td>Inclusion of phone numbers of the Poisons Information Centre in Australia and New Zealand.</td>
</tr>
</tbody>
</table>